Open Access

High correlation of the proteome patterns in bone marrow and peripheral blood blast cells in patients with acute myeloid leukemia

  • Gero Hütter1Email author,
  • Anne Letsch1,
  • Daniel Nowak1,
  • Julia Poland2,
  • Pranav Sinha2,
  • Eckhard Thiel1 and
  • Wolf-K Hofmann1
Journal of Translational Medicine20097:7

https://doi.org/10.1186/1479-5876-7-7

Received: 12 September 2008

Accepted: 15 January 2009

Published: 15 January 2009

Abstract

Background

When comparing myelogenous blasts from bone marrow and peripheral blood, immunophenotyping usually show a strong correlation of expression of surface antigens. However, it remains to be determined, whether this correlation also exists on the level of protein expression.

Method

Therefore, we investigated both bone marrow and peripheral blood blast cells from six patients with newly diagnosed acute myeloid leukemia (AML) using conventional two-dimensional electrophoresis in the first dimension and linear polyacrylamide gels (12%) in the second dimension. Proteins were visualized using the silver staining method and image analysis was performed using the PDQuest system.

Results

For each patient over 80 proteins were evaluated in the sample from peripheral blood and bone marrow. We could demonstrate that the protein expression profile of bone marrow did not significantly differ from the expression patterns of peripheral blast cells.

Conclusion

The proteome-set of leukemic blast cells from marrow and blood, does not differ substantially when drawn from AML patients with over 80 percent blast cells in both compartments. This indicates that in AML, blasts from peripheral blood samples can be considered suitable for investigations of the proteome using 2D-electrophoresis.

Background

Acute myeloid leukemia (AML) is an aggressive hematological neoplasia and it is characterized by accumulating myeloid precursor cells in bone marrow and detection of such cells in peripheral blood. Cytogenetics and molecular diagnostics are helpful for an individualized therapy in certain subsets of AML. There is hope that proteomics in AML will prompt new diagnostic or therapeutic biomarkers in future [1]. Up to date, the contribution of proteomics to the management of patients with AML is negligible although an enormous effort has been undertaken to develop databases of cancer proteins detected by two-dimensional gel electrophoresis [2]. They contain 2-D patterns and information from patients with lymphoproliferative disorders, leukemia, and a variety of other cell populations [36]. These databases were developed primarily from in vitro cell cultures. Experiences with corresponding in vivo samples are rare, even though cells from hematological disorders can easily be obtained for protein analysis. First investigations referring to the proteome of leukemia in vivo were undertaken from Hanash in the middle 80's. Hanash screened polypeptides as markers to distinguish acute lymphoblastic leukemia (ALL) cell lineages [7]. Later the proteomic approach was used to identify Hsp27, which distinguishes between ALL in infants and older children [8, 9]. Recently, Balkhi and co-workers were able to identify significant differences in the AML proteome between cytogenetic groups of this disease. They postulated, that analysis of the post-translational modifications could be useful to distinguish different subgroups of AML [10].

Studies employing immunophenotyping methods in acute myeloid leukemias (AML) have shown a strong correlation of surface antigen expression comparing bone marrow and peripheral blood blast cells [11]. However, it remains unclear, whether there are differences in expression levels on either protein or RNA-level which may indicate biological differences for both cell types.

In the present study, we aimed to investigate the profile of protein expression of blast populations from peripheral blood and bone marrow aspirates using a proteomic approach with 2D-electrophoresis in newly diagnosed patients with AML.

Materials and methods

Sample preparation and solubilization

Blast samples from bone marrow aspirates and peripheral blood were isolated from six patients with Ficoll-centrifugation and washed at least three times in large volumes of phosphate-buffered saline (Table 1). The cell pellet was solubilized according to Rabilloud in 9 M urea, 4% w/v CHAPS, and 20 mM spermine and 40 mM DTT [12]. After centrifugation to remove the precipitated nucleic acids, the supernatant was collected, for protein determination and for proteomic analysis.
Table 1

Patient and sample characteristics.

Patient

Sample-ID

Age

Gender

FAB-subtype

Karyotype

Source

WBC in μL (% blasts)

A

#02-05

60

Female

M2

t(8;21)

PB

4.8 (80%)

 

#02-02

    

BM

*

B

#02-06

22

Female

M2

normal

PB

379.0 (93%)

 

#02-03

    

BM

*

C

#02-24

63

Female

M5b

normal

PB

120.0 (91%)

 

#02-25

    

BM

*

D

#02-33

46

Male

M1

complex

PB

11.2 (85%)

 

#02-34

    

BM

*

E

#02-37

27

Female

M0

t(9;11)

PB

5.2 (81%)

 

#02-36

    

BM

*

F

#02-39

58

Male

M4

normal

PB

37.0 (87%)

 

#02-38

    

BM

*

WBC = white blood cell count, * = bone marrow samples were adjusted to 1.000.000 mononuclear cells per assay.

Protein determination

Since high concentration of urea and detergents interfere with any available protein assay system, we adapted a turbidimetric assay especially for samples prepared for 2D analysis[13]. In this assay, proteins are precipitated by trichloroacetic acid and measured turbidimetrically at 720 nm. Briefly, 35 ml of each sample was pipetted in duplicate in wells of a 96-well microtitre plates (Nunc, Denmark). One hundred ml of 0.1 M HCl was added to each well and the mixture shaken for 1 mm. Twenty five ml of 20% TCA was added to each well. The optical density was measured at 720 nm 5 min after TCA-addition using a standard Dynatech MR 7000 ELISA photometer (Dynatech, Hamburg). For evaluation, a non-linear standard curve with protein concentrations of 0.2, 1, 2 and 5 mg/ml was used. Control material from Boehringer Mannheim (Precinorm protein control serum) was used to obtain the standard curves that were run with each determination.

First dimension isoelectric focusing (IEF)

First dimension glass tubes were placed in the Hoefer cast-system. Solution for IEF contains 8.24 g urea, 1.95 ml acrylamide solution (T = 28.38%, C = 1.92%)1, 600 μl carrier-ampholyte (CA) 5–7 (Servalyt), 200 μl CA 3.5–10 (Pharmacia), 3 ml Triton X 10%, 20 μl TEMED, and 30 μl ammonium persulfate 10%. The cathodic chamber was filled with 10 mM of sodium hydroxide and the anodic chamber with 3.26 ml phosphoric acid 85%. The solution for the overlay contained 20% glycerol and 2% CA. Focusing started with 200 V for 15 minutes, followed by 300 V for 30 minutes and finally with 400 V for 60 minutes. After IE-focusing, the sample was added on the cathodic side of the tube gel. The aliquot of the sample contained a total of 10 μg of protein. Electrophoresis started with 200 V for 15 minutes, followed by 300 V for 30 minutes and finally 400 V for 12 hours.

Second dimension SDS-page

Tube-gels were sealed on top of linear polyacrylamide gels (T = 30%, C = 2%) using a sealing solution (1% agarose, 0.2% SDS, 0.15 M Bis/Tris, 0.1 M HCl). The Iso-Dalt System contained a buffer of 58 g tris base, 299 g glycine, and 100 ml SDS 20%. The run was completed at 20 mA/gel until the tracking dye reached the bottom of the gel [14]. After electrophoresis, the gels were fixed in 50% ethanol, and 10% acetic acid for 12 hours.

Silver staining

Proteins were visualized using the silver staining method employing a modification of the method of Heukeshoven according to Sinha et al. [15, 16].

Image Analysis and Spot Identification

Image analysis was performed using the PDQuest system according to the protocols provided by the manufacturer after scanning with the densitometer GS-710 (Bio-Rad, CA, USA), the spot pattern of each patient sample was summarized in a gel image. For protein identification, each gel image was matched to the previously 130 identified spots of the gastric carcinoma cell line EPG85-257 [17]. To yield information about changes in the protein expression gel images of peripheral and blood sample for each patient were matched. The following criteria for differential protein expression were used: (i) spot intensity: four-fold increased = differential overexpression; (ii) spot intensity: four-fold decreased = differential under-expression.

Results

Matching of samples

In the pH range 4.0–8.0, conventional 2-D electrophoresis of the 12 samples yielded about 700–900 spots, respectively (Figure 1). We were able to identify a maximum of 107 proteins in the AML samples. 23 Spots of the gastric cancer cell line were not represented in the AML samples.
Figure 1

2-D pattern of the silver stained gel image of the master gel image. 2-D pattern of the silver stained gel image of a master gel image containing the spot information of all investigated samples. For protein identification, each gel image was matched to the previously 130 identified spots of the gastric carcinoma cell line EPG85-257. Proteins identified to date are marked with arrows and numbered according to Sinha et al. [17].

Intra-individual analysis of the spot patterns showed a high correlation between the sample from peripheral blood and bone marrow (Table 2). On/off-phenomena of the identified spots were observed in four cases: Spot No. 19 (annexin 6) was found in patient A in the sample of peripheral blood but not in bone marrow, in patient B an inverse constellation was detected concerning this protein (Figure 2). As a third variance an absence of spot No. 102 (phosphoglyceromutase) was only found in the bone marrow of patient B. The fourth change concerned spot No. 130 (vimentin) which was only represented in the peripheral blood sample of patient B.
Table 2

Different protein expression in AML.

 

Patient/Sample-No.

A

B

C

D

E

F

Spot-No.

Protein

#02-05p

#02-02b

#02-06p

#02-03b

#02-24p

#02-25b

#02-33p

#02-34b

#02-37p

#02-36b

#02-39p

#02-38b

5

14-3-3 related

    

+

+

      

19

Annexin 6, Calectrin (67 kDa)

+

  

+

+

+

+

+

+

+

+

+

60

FK506 binding protein 4

+

+

+

+

+

+

  

+

+

+

+

91

Ku antigen (86 kDa)

+

+

+

+

  

+

+

+

+

+

+

102

Phosphoglyceromutase

+

+

 

+

+

+

+

+

+

+

+

+

103

Plasminogen activator inhibitor-2

        

+

+

+

+

104

Plasminogen activa. inhib.-2 var.

        

+

+

+

+

115

Rho A

*

*

+

+

  

+

+

+

+

+

+

121

TCHTP

      

*

*

+

+

  

122

TCHTP var.

      

*

*

  

+

+

130

Vimentin

+

+

 

+

+

+

+

+

+

+

+

+

Figure 2

Detail of the two-dimensional patterns of patient A. Detail of the two-dimensional patterns of patient A. Different expression of spot 19 (annexin 6) in the bone marrow sample in comparison to peripheral blood.

In addition, for the patients A, B and E with refractory leukemia, there were additional samples available from the time of relapse. The intervals for the date of collection from the first sample were: 6 months for patient A, 14 days for patient B, and 3 days for patient E. Analysis of the spot patterns from these samples showed an identical profile as compared to the previously collected samples of the same individual (data not shown).

Six proteins with two additional variants were found to be expressed differentially within bone marrow and peripheral blood cells of selected individuals (Table 2). Spot No. 5 (14-3-3 related) was only present in patient C, spot No. 121 and 122 (TCHTP and variant) was only present in patient F and G, respectively. Spot 60 (FK506 binding protein 4) was absent in patient D and spots No. 91 (Ku antigen) and 115 (Rho A) were not present in patient C (Figure 3). Furthermore, only patients F and G showed an expression of plasminogenactivator inhibitor-2 and a variant (spots 103 and 104).
Figure 3

Detail of the two-dimensional patterns with different expression of the Ku antigen. Selective deficiency of spot 91 (Ku antigene, marked with an arrow) in patient C whereas expression is detectable in other patients irrespectively of sample origin.

Discussion

Analysis of cell populations in vivo can provide the highest degree of fidelity for a snapshot of the protein changes that occur as a cause or consequence of the malignancy. Proteins rather than genes or mRNAs represent the key players in the cell. Expression levels of proteins determine the cellular phenotype and its plasticity in response to external signals. The aim of this study was to investigate the protein expression profiles of myelogenous blasts from patients with AML collected from two compartments, bone marrow and peripheral blood.

We previously used a cell culture model derived from thermoresistant gastric cancer to build up a database for 2D-electrophoresis patterns [17]. After matching the gel images of the AML samples with the images of the gastric cancer cell line, we found some differences in the protein patterns but overall, these changes were small: Seven proteins (with two variants) were clearly defined in the gastric carcinoma cell line but not in the AML samples (Spots-No. 4, 64, 103, 108, 114, 121, 123) (Table 3). The majority of these proteins have unspecific or unknown functions or they are clearly related to tissues and not to hematological cells [1823].
Table 3

Proteins as expressed in the gastric cell line but not in AML.

No.

Protein name

General function

Ref.

4

14-3-3σ

Adapter protein for phosphoserin motifs. Regulated the interactions and subcellular localization of signalling molecules.

[18]

64

γ-Catenin

Forms a complex with α- and β-Catenin to Cadherins, that are involved in the formation and maintenance of the histo-architecture.

[19]

103

Plasmonogen activator inhibitor-2 (PAI-2)

Involved in the regulation and inhibition of binding between urokinase-type plasminogen activator and its receptor, involved in physiological and pathological proteolysis and extracellular matrix degradation.

[20]

108

Proteasome δ

Cleavage at peptide bonds with very broad specificity

[21]

114

Reticulocalbin (RCN)

RCN is a member of the EF-hand Ca(2+)-binding protein family and may regulate calcium-dependent activities in the endoplasmatic reticulum lumen or post-ER compartment

[22]

121

TCHTP

Cytoplasmatic Ca2(+)-binding protein

[23]

123

Transgelin 2

Unknown

 

As an example, protein spot No. 4 (14-3-3σ) is a family member of proteins that regulate cellular activity by binding and sequestering phosphorylated proteins. 14-3-3σ promotes pre-mitotic cell-cycle arrest following DNA damage, and its expression can be controlled by the p53 tumor-suppressor gene [24]. None of the investigated AML-samples exhibited a 14-3-3σ expression in the 2D pattern. Analysis of other AML samples which did not meet the inclusion criteria for this investigation showed similar results: the expression of 14-3-3σ in AML blast is an infrequent event. This observation corresponds to investigations in breast cancer and small cell lung carcinoma. In breast cancer a hypermethylation of the CpG island of the σ gene was found that leads to gene silencing and absence of 14-3-3σ. The authors conclude, that the loss of σ expression contributes to malignant transformation by impairing the G2 cell cycle checkpoint function, thus allowing an accumulation of genetic defects [25, 26].

Interestingly, there were only marginal differences in the expression profiles comparing patient to patient. This was also observed in studies with patients with B-cell chronic lymphocytic leukemia (CLL). In CLL, analysis allowed the identification of proteins that clearly discriminated between the patients groups with defined chromosomal characteristics or clinical parameters such as patient survival [27].

Expression of the plasminogen activator inhibitor-2 (PAI-2) was only found in patients E and F with the subtyp FAB M0 and M4, respectively. This finding is inline with data from the PAI-2 serum levels of patients with hematological malignancies, where different expression levels were correlated with different serum levels for PAI-2 in the AML subtypes FAB M4 and M0 [28]. As an explanation it was postulated, that myeloid blasts, like their non-tumoral counterparts, monocytes/macrophages, are able to synthesize most components of the plasminogen activation system. Among the numerous features shared by normal monocytes and M4 cells were the capability to migrate to areas of inflammation and to infiltrate extramedullary tissues like gingival enlargement [29].

Furthermore, we have observed that the protein patterns from samples from bone marrow and peripheral blood from the same patient show a high correlation. The observed changes are marginal and inter-individually variable.

Conclusion

In conclusion, the protein expression profile in AML blasts collected from bone marrow aspirates in comparison to blasts from peripheral blood samples do not differ basically. This may indicate, that samples of peripheral blood with high amounts of blasts are to be considered suitable for investigations of the proteome using 2D-electrophoresis. Furthermore, protein expression profiling is likely to further impact the analysis of mechanisms involved in acute leukemia by examining routinely available biological material.

Note

1%T = [(acrylamide + bis-acrylamide) × 100]/total weight

%C = (bis-acrylamide × 100)/(bis-alcrylamide + acrylamide)

Declarations

Acknowledgements

This work was supported by a grant from the Deutsche José Carreras Leukämie Stiftung, Munich, Germany (SP 03/06).

Authors’ Affiliations

(1)
Department of Internal Medicine III (Hematology, Onkology), Charité Berlin Campus Benjamin Franklin
(2)
Institute of Laboratory Medicine and Clinical Chemistry, LKH Klagenfurt

References

  1. Sjoholt G, Anensen N, Wergeland L, Mc Cormack E, Bruserud O, Gjertsen BT: Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Curr Drug Targets. 2005, 6 (6): 631-646. 10.2174/1389450054863671.View ArticlePubMedGoogle Scholar
  2. Czibere A, Grall F, Aivado M: Perspectives of proteomics in acute myeloid leukemia. Expert Rev Anticancer Ther. 2006, 6 (11): 1663-1675. 10.1586/14737140.6.11.1663.View ArticlePubMedGoogle Scholar
  3. Hanash SM, Teichroew D: Mining the human proteome: experience with the human lymphoid protein database. Electrophoresis. 1998, 19 (11): 2004-2009. 10.1002/elps.1150191119.View ArticlePubMedGoogle Scholar
  4. Hanash SM, Madoz-Gurpide J, Misek DE: Identification of novel targets for cancer therapy using expression proteomics. Leukemia. 2002, 16 (4): 478-485. 10.1038/sj.leu.2402412.View ArticlePubMedGoogle Scholar
  5. Lefkovits I, Kettman JR, Coleclough C: A strategy for founding a global lymphocyte proteinpaedia and gene catalogue. Immunol Today. 1990, 11 (5): 157-162. 10.1016/0167-5699(90)90066-I.View ArticlePubMedGoogle Scholar
  6. Kettman JR, Coleclough C, Lefkovits I: Lymphocyte Proteinpaedia stage two: T-cell polypeptides from a partitioned cDNA library revealed by the dual decay method. Int Arch Allergy Immunol. 1994, 103 (2): 131-142.View ArticlePubMedGoogle Scholar
  7. Hanash SM, Baier LJ, McCurry L, Schwartz SA: Lineage-related polypeptide markers in acute lymphoblastic leukemia detected by two-dimensional gel electrophoresis. Proc Natl Acad Sci USA. 1986, 83 (3): 807-811. 10.1073/pnas.83.3.807.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Hanash SM, Kuick R, Strahler J, Richardson B, Reaman G, Stoolman L, Hanson C, Nichols D, Tueche HJ: Identification of a cellular polypeptide that distinguishes between acute lymphoblastic leukemia in infants and in older children. Blood. 1989, 73 (2): 527-532.PubMedGoogle Scholar
  9. Strahler JR, Kuick R, Hanash SM: Diminished phosphorylation of a heat shock protein (HSP 27) in infant acute lymphoblastic leukemia. Biochem Biophys Res Commun. 1991, 175 (1): 134-142. 10.1016/S0006-291X(05)81211-2.View ArticlePubMedGoogle Scholar
  10. Balkhi MY, Trivedi AK, Geletu M, Christopeit M, Bohlander SK, Behre HM, Behre G: Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene. 2006, 25 (53): 7041-7058. 10.1038/sj.onc.1209689.View ArticlePubMedGoogle Scholar
  11. Griffin JD, Davis R, Nelson DA, Davey FR, Mayer RJ, Schiffer C, McIntyre OR, Bloomfield CD: Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood. 1986, 68 (6): 1232-1241.PubMedGoogle Scholar
  12. Rabilloud T: Use of thiourea to increase the solubility of membrane proteins in two-dimensional electrophoresis. Electrophoresis. 1998, 19 (5): 758-760. 10.1002/elps.1150190526.View ArticlePubMedGoogle Scholar
  13. Cheung CK, Mak YT, Swaminathan R: Automated trichloroacetic acid precipitation method for urine total protein. Ann Clin Biochem. 1987, 24 (Pt 2): 140-144.View ArticlePubMedGoogle Scholar
  14. Celis JE, Gesser B, Dejgaard K, Honore B, Leffers H, Madsen P, Andersen A, Basse B, Celis A, Lauridsen JB: Two dimensional gel human protein databases offer a systematic approach to the study of cell proliferation and differentiation. Int J Dev Biol. 1989, 33 (4): 407-416.PubMedGoogle Scholar
  15. Klose J, Kobalz U: Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis. 1995, 16 (6): 1034-1059. 10.1002/elps.11501601175.View ArticlePubMedGoogle Scholar
  16. Sinha P, Poland J, Schnolzer M, Rabilloud T: A new silver staining apparatus and procedure for matrix-assisted laser desorption/ionization-time of flight analysis of proteins after two-dimensional electrophoresis. Proteomics. 2001, 1 (7): 835-840. 10.1002/1615-9861(200107)1:7<835::AID-PROT835>3.0.CO;2-2.View ArticlePubMedGoogle Scholar
  17. Sinha P, Poland J, Schnolzer M, Celis JE, Lage H: Characterization of the differential protein expression associated with thermoresistance in human gastric carcinoma cell lines. Electrophoresis. 2001, 22 (14): 2990-3000. 10.1002/1522-2683(200108)22:14<2990::AID-ELPS2990>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
  18. Ferl RJ, Manak MS, Reyes MF: The 14-3-3s. Genome Biol. 2002, 3 (7):Google Scholar
  19. Ozawa M: Identification of the region of alpha-catenin that plays an essential role in cadherin-mediated cell adhesion. J Biol Chem. 1998, 273 (45): 29524-29529. 10.1074/jbc.273.45.29524.View ArticlePubMedGoogle Scholar
  20. Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000, 57 (1): 25-40. 10.1007/s000180050497.View ArticlePubMedGoogle Scholar
  21. Ding Q, Reinacker K, Dimayuga E, Nukala V, Drake J, Butterfield DA, Dunn JC, Martin S, Bruce-Keller AJ, Keller JN: Role of the proteasome in protein oxidation and neural viability following low-level oxidative stress. FEBS Lett. 2003, 546 (2–3): 228-332. 10.1016/S0014-5793(03)00582-9.View ArticlePubMedGoogle Scholar
  22. Ozawa M, Muramatsu T: Reticulocalbin, a novel endoplasmic reticulum resident Ca(2+)-binding protein with multiple EF-hand motifs and a carboxyl-terminal HDEL sequence. J Biol Chem. 1993, 268 (1): 699-705.PubMedGoogle Scholar
  23. Reymond MA, Sanchez JC, Hughes GJ, Gunther K, Riese J, Tortola S, Peinado MA, Kirchner T, Hohenberger W, Hochstrasser DF: Standardized characterization of gene expression in human colorectal epithelium by two-dimensional electrophoresis. Electrophoresis. 1997, 18 (15): 2842-2848. 10.1002/elps.1150181520.View ArticlePubMedGoogle Scholar
  24. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999, 401 (6753): 616-620. 10.1038/44188.View ArticlePubMedGoogle Scholar
  25. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M, Takahashi T: Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene. 2002, 21 (15): 2418-2424. 10.1038/sj.onc.1205303.View ArticlePubMedGoogle Scholar
  26. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR: High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA. 2000, 97 (11): 6049-6054. 10.1073/pnas.100566997.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Voss T, Ahorn H, Haberl P, Dohner H, Wilgenbus K: Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int J Cancer. 2001, 91 (2): 180-186. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1037>3.0.CO;2-J.View ArticlePubMedGoogle Scholar
  28. Scherrer A, Kruithof EK, Grob JP: Plasminogen activator inhibitor-2 in patients with monocytic leukemia. Leukemia. 1991, 5 (6): 479-486.PubMedGoogle Scholar
  29. Scherrer A, Wohlwend A, Kruithof EK, Vassalli JD, Sappino AP: Plasminogen activation in human acute leukaemias. Br J Haematol. 1999, 105 (4): 920-927. 10.1046/j.1365-2141.1999.01432.x.View ArticlePubMedGoogle Scholar

Copyright

© Hütter et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.